Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%

ABBOTT LABORATORIES

2023-Q2 EPS reported $1.53 revenue$19,725,000,000

Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).
Underlying base business organic sales growth 11.5% led by Medical Devices (+14.2% organic) and Nutrition (+9.9% organic).
Full-year 2023 adjusted EPS guidance reaffirmed at $4.30-$4.50; COVID testing sales forecast $1.3B.
FreeStyle Libre sales $1.3B, up 24.7% organic; new product approvals: TactiFlex, AVEIR dual-chamber pacemaker.
Quarterly dividend $0.51/share declared, payable Aug 15, 2023; 51 consecutive years of increases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABBOTT LABORATORIES reported second quarter 2023 results: revenue $10.0 billion, EPS $0.78.

Period: second quarter 2023
Revenue: $10.0 billion
EPS: $0.78
Result: reported results

Exact text from the filing

in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –

View on SEC.gov

Browse all earnings releases →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001628280-23-025156

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.